Bio City Development

BioCity is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for oncology and chronic diseases, with a primary focus on chronic kidney disease (CKD). The company leverages its proprietary antibody-drug conjugate (ADC) and antibody discovery platforms to advance a robust pipeline of first-in-class and best-in-class candidates. Its lead oncology program, BC3195, is a CDH3-targeted ADC currently in Phase 1 trials, while its lead nephrology candidate, SC0062, is a highly selective endothelin A receptor antagonist in Phase 2 development. BioCity maintains a global presence with research and clinical operations in China and the United States, aiming to address significant unmet medical needs in global markets.